Anti-integrin alphaVbeta6 antibody titer and the development of ulcerative colitis: a prospective multicenter study in Japan

Anti-integrin alphaVbeta6 antibody titer and the development of ulcerative colitis: a prospective multicenter study in Japan - Anti-integrin alphaVbeta6 antibody titer and ulcerative colitis in the Japanese prospective cohort

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000056773

Enrollment

6000

Registered

2025-01-23

Start date

2024-04-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative colitis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Subjects who enroll in the faculties of universities or colleges related to research institutions from 2024 to 2028. The starting year for eligible students is the year in which ethics committee approval is obtained at each facility.

Exclusion criteria

Exclusion criteria: Subjects who do not consent to participate in the study.

Design outcomes

Primary

Measure	Time frame
Association between anti-integrin alphaVbeta6 antibody and the development of ulcerative colitis	—

Secondary

Measure	Time frame
-Anti-integrin alphaVbeta6 antibody positive rate -Association between anti-integrin alphaVbeta6 antibody and ulcerative colitis prevalence	—

Countries

Japan

Contacts

Public ContactJun Miyoshi

Kyorin University School of Medicine Department of Gastroenterology and Hepatology

jmiyoshi@ks.kyorin-u.ac.jp0422-47-5511

Outcome results